Promea Therapeutics Private Limited

Promea Therapeutics Private Limited - healthcare in Patancheru, Telangana, India. FY 2026 financials & compliance.
CIN U24304TG2017PTC118617 Incorporated 31 July 2017 ROC Hyderabad HQ Patancheru, Telangana, India
Active Private Limited Company healthcare DPIIT Startup MSME · Medium
Data last updated
Revenue · FY 2023
₹56.78 Cr
▲ 98% YoY
Net loss · FY 2023
₹1.17 Cr
Net margin -2.1%
EBITDA · FY 2023
₹11.38 Cr
EBITDA margin 20.1%
Authorised capital
₹4 Cr
Registered with MCA
Paid-up capital
₹3.86 Cr
Issued & subscribed
Open charges
₹58.19 Cr
Secured borrowings
Company age
9 yrs
Est. 2017
Employees · EPFO
174
Provident fund records

About Promea Therapeutics Private Limited

Data last updated:

Promea Therapeutics Private Limited is a private limited company based in Patancheru, Telangana, India, recognised as a startup by DPIIT. It operates in the medical and laboratory equipment segment of the healthcare sector. It was incorporated on 31 July 2017 and has been in existence for over 9 years.

The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24304TG2017PTC118617. Its GSTIN is 36AAJCP3437C1ZK (Telangana).

The company has an authorised share capital of ₹4 Cr and a paid-up capital of ₹3.86 Cr. It is led by directors Rajesh Reddy Tummuru and Pooja Aakanksha Gaddam.

Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at M4 Medical Device Park, Patancheru, Telangana.

As per the financials filed for FY 2023, the company reported a revenue of ₹56.78 Cr, a growth of 98% compared to the previous year. For the same year it recorded a net loss of ₹1.17 Cr (net margin -2.1%) and EBITDA of ₹11.38 Cr (EBITDA margin 20.1%). Revenue has grown at a compounded annual rate (CAGR) of 60% over three years and 95% over five years.

The company has about 174 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Promea Therapeutics. As per MCA filings, the company has open charges of ₹58.19 Cr on record. Court records list 2 cases involving the company, including 1 filed by the company and 1 filed against it. The company has 2 deals on record (1 funding round, 1 secondary share transfer), with disclosed funding of ₹3.86 Cr; the latest was in March 2019.

Promea Therapeutics Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-TS-09-0002143). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website promea.in.

Company details

CIN U24304TG2017PTC118617
Registration Number 118617
Incorporation Date 31 July 2017
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
DPIIT Recognition Recognised Startup
MSME Classification Medium
Udyam Registration UDYAM-TS-09-0002143
Key People
Rajesh Reddy Tummuru Director Pooja Aakanksha Gaddam Director

Recognitions & Rankings of Promea Therapeutics

DPIIT recognised startup Government of India
Startup India
MSME (Udyam registered) Ministry of MSME
Category
Medium (2022-23)
Udyam number
UDYAM-TS-09-0002143

Contact details

Promea Therapeutics Private Limited's registered office is in Patancheru, Telangana. Its website is promea.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    promea.in
  • Social Media
  • Registered Address
    Plot No. M4 Medical Device Park, Sultanpur (V), Patancheru, Telangana, India – 502319
  • Industry
    Healthcare, Medical & Laboratory Equipment

To see the full contact details of Promea Therapeutics Private Limited, buy the company report.

Comprehensive company report
Promea Therapeutics Private Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Promea Therapeutics operates one associated brand: Promea Therapeutics. Each brand links to its own profile.

BrandDescriptionWebsite
Promea Therapeutics
Life science products and diagnostics are manufactured by the company.promea.in

Financials of Promea Therapeutics Private Limited

FY 2025 filings available

Promea Therapeutics Private Limited reported revenue of ₹56.78 Cr (up 98% YoY) for FY 2023.

Revenue · FY 2023
₹56.78 Cr ▲ 98%
Net loss · FY 2023
₹1.17 Cr margin -2.1%
EBITDA · FY 2023
₹11.38 Cr margin 20.1%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▲ 98%
3 years · compounded
▲ 60%
5 years · compounded
▲ 95%
EBITDA CAGR growth
1 year
▲ 225%
3 years · compounded
▲ 38%

Revenue has grown at a compounded annual rate (CAGR) of 95% over five years, including 98% growth in the latest year. EBITDA rose 225% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2022-23FY 2021-22FY 2020-21FY 2019-20FY 2018-19
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue₹56.78 Cr
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA₹11.38 Cr
Profit Before Tax
Tax Expense
Net Profit (PAT)-₹1.17 Cr
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2022-23FY 2021-22FY 2020-21FY 2019-20FY 2018-19
Profitability
EBITDA Margin20.1%
Net Profit Margin-2.1%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Promea Therapeutics Private Limited, buy the company report.

Board of directors of Promea Therapeutics Private Limited

Promea Therapeutics has 2 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Rajesh Reddy Tummuru
Also directs: Lekcon Farms LLP, Bionutra Private Limited, Cytobiologics Private Limited and 5 more
Director09 Oct 20179 Years 0 MonthsCurrent
Pooja Aakanksha Gaddam
Also directs: Promea Care Private Limited, Sr Prime Infrastructure LLP, Sivika Foods Private Limited and 3 more
Director31 Jul 20179 Years 3 MonthsCurrent
View all directors

Auditor

Promea Therapeutics Private Limited is audited by akasam & associates for the financial year 2023.

Auditor firmFinancial yearFirm registration number
akasam & associatesFY 2023005832S

Shareholding

The shareholding of Promea Therapeutics Private Limited is on record for 5 financial years, the latest being FY 2022, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2022FY 2021FY 2020FY 2019FY 2018
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of Promea Therapeutics Private Limited, buy the company report.

Charges & borrowings

Open charges
₹58.19 Cr
Satisfied charges
None
Breakdown by lending institutions
Others₹56.16 Cr
Axis Bank Limited₹2.03 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
11 Jun 2025101180880Axis Bank Limited₹28 LakhOpen
01 Jul 2024100955463Others₹36.08 CrOpen
29 Dec 2022100695360Axis Bank Limited₹1.75 CrOpen
24 May 2021100470484Others₹20.08 CrOpen

To see the full charge records of Promea Therapeutics Private Limited, buy the company report.

Total charge records: 4 View all charges

Deals & funding

Promea Therapeutics Private Limited has 2 deals on record (1 funding round, 1 secondary share transfer), with disclosed funding of ₹3.86 Cr; the latest was in March 2019.

Total deals
2
Funding round
1
Secondary share transfer
1
Disclosed funding
₹3.86 Cr

Deals on record (2 of 2)

WhenDealAmountParties
Mar 2019Secondary share transferUndisclosedBuyer: 2 individuals
Seller: 2 individuals
Jul 2018Funding round₹3.86 CrInvestors: 4 individuals

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Promea Therapeutics Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

Employees & EPFO

Promea Therapeutics Private Limited has a workforce of 174 employees on its EPFO records as of Apr 06, 2024, across 1 active EPFO establishment.

Employee count
174
Active EPFO establishments
1
Employee growth
16.78%

GST

Promea Therapeutics has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
36AAJCP3437C1ZKTelanganaActive01 Feb 2018

To see the full GST registrations and return filing status of Promea Therapeutics Private Limited, buy the company report.

Recent activity

Promea Therapeutics Private Limited has 3 board changes on record since 2017: 2 appointments and 1 cessation. The latest: Gaddam Reddy Ranjith ceased to be Director on 27 Sep 2018.

AGM
Promea Therapeutics Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Charges
A charge with Axis Bank Limited amounted to Rs. 0.28 Cr with Charge ID 101180880 was registered on 11 Jun 2025.
Charges
A charge with Others of Rs. 36.08 Cr registered on 01 Jul 2024 with Charge ID 100955463 was modified on 28 May 2025.
Filing
Promea Therapeutics Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Charges
A charge with Others of Rs. 20.08 Cr registered on 24 May 2021 with Charge ID 100470484 was modified on 30 Jan 2025.
Charges
A charge with Others amounted to Rs. 36.08 Cr with Charge ID 100955463 was registered on 01 Jul 2024.
Charges
A charge with Axis Bank Limited amounted to Rs. 1.75 Cr with Charge ID 100695360 was registered on 29 Dec 2022.
Charges
A charge with Others amounted to Rs. 20.08 Cr with Charge ID 100470484 was registered on 24 May 2021.
Ceased
Gaddam Reddy Ranjith ceased to be Director.
Appointed
Rajesh Reddy Tummuru was appointed as Director.
Appointed
Pooja Aakanksha Gaddam was appointed as Director.
Incorporation
31 Jul 2017
Promea Therapeutics Private Limited was registered on 31 Jul 2017 with Roc Hyderabad & aged 9 years 3 months as per MCA records.

Frequently asked questions

Promea Therapeutics is an active private limited company based in Patancheru, Telangana, India. The company works in medical and laboratory equipment, within the healthcare industry. It was incorporated on 31 July 2017 (9+ years old) and is registered under CIN U24304TG2017PTC118617.

Promea Therapeutics has 2 current directors:

The latest financial statements of Promea Therapeutics on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2018 are in the company report.

The GSTIN of Promea Therapeutics is 36AAJCP3437C1ZK, registered in Telangana.

The CIN (Corporate Identification Number) of Promea Therapeutics is U24304TG2017PTC118617. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Promea Therapeutics has 2 court cases on record: 1 filed by the company and 1 filed against it.

Promea Therapeutics was incorporated on 31 July 2017, making it 9+ years old. It is registered with the Registrar of Companies, Hyderabad.

Promea Therapeutics has 2 deals on record (1 funding round, 1 secondary share transfer), with disclosed funding of ₹3.86 Cr; the latest was in March 2019.

Gaddam Reddy Ranjith ceased to be Director on 27 Sep 2018. Rajesh Reddy Tummuru was appointed as Director on 09 Oct 2017. Pooja Aakanksha Gaddam was appointed as Director on 31 Jul 2017.

Yes, Promea Therapeutics is recognised as a startup by the Department for Promotion of Industry and Internal Trade (DPIIT).